End-to-end Drug Design
Spektron Systems implements end-to-end drug design using powerful AI-based methods to generate de-risked molecular designs before any compound is synthesized.
The first step in developing a molecule that could become a best-in-class therapy is finding the building blocks of the vocabulary associated with the therapeutic effect. Spektron uses a multi-model approach, spanning models from clinical metrics to receptor binding, to develop the relationships between compounds and their effects.
Enriched Virtual Screening Library Development
Once we develop the molecular vocabulary, we develop novel compounds with designs directly informed from